日本国内発症進行性多巣性白質脳症のサーベイランスの現状と疾患修飾薬治療に伴う多巣性白質脳症

DOI
  • 三浦 義治
    がん・感染症センター都立駒込病院脳神経内科

書誌事項

タイトル別名
  • PML surveillance registration system in Japan and DMD–associated PML

この論文をさがす

抄録

<p>Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by JC polyomavirus (JCV). In Japan, the incidence of PML has been investigated by us, a Health and Labour Sciences Research Grant for Research on Measures for Intractable Diseases (Prion Disease and Slow Virus Infections) from the Ministry of Health, Labour and Welfare of the Japanese government. Recently, we have established registration system on PML Surveillance Committee. This system makes epidemiological investigation effective and exact. In Japan the basic disease of PML are changing variously. The major basic diseases are hematologic disease/malignancy such as lymphoma, collagen disease/autoimmune disease as SLE, HIV infection, MS and kidney disease. Four fingolimod–associated PML cases and one natalizumab–associated PML are reported in Japan. Next, we have established new criteria for the diagnosis of PML by PML Practice guideline 2017. Clinical diagnosis criteria consist of clinical feature, neuroradiographic imaging, excluded criteria, and the presence of the virus in the CSF compartment. In histopathological diagnosis criteria, Definitive diagnosis of PML requires neuropathologic demonstration of the typical histopathologic triad (demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei) coupled with the techniques to show the presence of JC virus. Furthermore, Nakamichi et al established ultrasensitive PCR assay in detection of JCV DNA in the cerebrospinal fluid. Shishido–Hara et al are accepting of consultation of pathological examination form attending doctors and pathologists. These measures will be helpful for the new DMD–associated PML.</p>

収録刊行物

  • 神経治療学

    神経治療学 35 (4), 508-512, 2018

    日本神経治療学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ